Karunya Kandimalla to Alzheimer Disease
This is a "connection" page, showing publications Karunya Kandimalla has written about Alzheimer Disease.
Connection Strength
4.676
-
Wang Z, Sharda N, Omtri RS, Li L, Kandimalla KK. Amyloid-Beta Peptides 40 and 42 Employ Distinct Molecular Pathways for Cell Entry and Intracellular Transit at the Blood-Brain Barrier Endothelium. Mol Pharmacol. 2023 Nov; 104(5):203-213.
Score: 0.563
-
Zhou AL, Sharda N, Sarma VV, Ahlschwede KM, Curran GL, Tang X, Poduslo JF, Kalari KR, Lowe VJ, Kandimalla KK. Age-Dependent Changes in the Plasma and Brain Pharmacokinetics of Amyloid-? Peptides and Insulin. J Alzheimers Dis. 2022; 85(3):1031-1044.
Score: 0.505
-
Wang Z, Sharda N, Curran GL, Li L, Lowe VJ, Kandimalla KK. Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium. Mol Pharm. 2021 11 01; 18(11):4148-4161.
Score: 0.497
-
Ahlschwede KM, Curran GL, Rosenberg JT, Grant SC, Sarkar G, Jenkins RB, Ramakrishnan S, Poduslo JF, Kandimalla KK. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. Nanomedicine. 2019 02; 16:258-266.
Score: 0.403
-
Omtri RS, Thompson KJ, Tang X, Gali CC, Panzenboeck U, Davidson MW, Kalari KR, Kandimalla KK. Differential Effects of Alzheimer's Disease A?40 and 42 on Endocytosis and Intraneuronal Trafficking. Neuroscience. 2018 03 01; 373:159-168.
Score: 0.383
-
Jaruszewski KM, Curran GL, Swaminathan SK, Rosenberg JT, Grant SC, Ramakrishnan S, Lowe VJ, Poduslo JF, Kandimalla KK. Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. Biomaterials. 2014 Feb; 35(6):1967-76.
Score: 0.289
-
Agyare EK, Leonard SR, Curran GL, Yu CC, Lowe VJ, Paravastu AK, Poduslo JF, Kandimalla KK. Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-? proteins in the cerebral vasculature. Mol Pharm. 2013 May 06; 10(5):1557-65.
Score: 0.274
-
Omtri RS, Davidson MW, Arumugam B, Poduslo JF, Kandimalla KK. Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: ramifications for the Alzheimer's drug discovery. Mol Pharm. 2012 Jul 02; 9(7):1887-97.
Score: 0.260
-
Poduslo JF, Gilles EJ, Ramakrishnan M, Howell KG, Wengenack TM, Curran GL, Kandimalla KK. HH domain of Alzheimer's disease Abeta provides structural basis for neuronal binding in PC12 and mouse cortical/hippocampal neurons. PLoS One. 2010 Jan 21; 5(1):e8813.
Score: 0.220
-
Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF. Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. PLoS One. 2009; 4(2):e4627.
Score: 0.207
-
Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm Res. 2008 Nov; 25(11):2674-84.
Score: 0.200
-
Kandimalla KK, Wengenack TM, Curran GL, Gilles EJ, Poduslo JF. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice. J Pharmacol Exp Ther. 2007 Aug; 322(2):541-9.
Score: 0.183
-
Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Ramirez-Alvarado M, Poduslo JF. Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid beta40. J Pharmacol Exp Ther. 2006 Jul; 318(1):17-25.
Score: 0.169
-
Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther. 2005 Jun; 313(3):1370-8.
Score: 0.157
-
Swaminathan SK, Ahlschwede KM, Sarma V, Curran GL, Omtri RS, Decklever T, Lowe VJ, Poduslo JF, Kandimalla KK. Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. J Cereb Blood Flow Metab. 2018 05; 38(5):904-918.
Score: 0.092
-
Poduslo JF, Howell KG, Olson NC, Ramirez-Alvarado M, Kandimalla KK. Alzheimer's disease amyloid ?-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils. Biochemistry. 2012 May 15; 51(19):3993-4003.
Score: 0.065
-
Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine. 2012 Feb; 8(2):250-60.
Score: 0.061
-
Ramakrishnan M, Kandimalla KK, Wengenack TM, Howell KG, Poduslo JF. Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies. Biochemistry. 2009 Nov 03; 48(43):10405-15.
Score: 0.054
-
Ramakrishnan M, Wengenack TM, Kandimalla KK, Curran GL, Gilles EJ, Ramirez-Alvarado M, Lin J, Garwood M, Jack CR, Poduslo JF. Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging. Pharm Res. 2008 Aug; 25(8):1861-72.
Score: 0.049
-
Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ, Curran GL, Wengenack TM. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem. 2007 Jul; 102(2):420-33.
Score: 0.046